Biosimilars open $74B market by 2030

Biosimilars are the “generic” version of a much harder class of drugs — biologics made in living cells, not small molecules mixed in a chemistry vat. That matters because the next few years bring a real patent cliff for blockbuster biologics, especially in cancer. The biggest name in that wave is Merck’s Keytruda, which did $31.7 billion in 2025 sales and is expected to face U.S. loss of exclusivity in 2028. Suddenly, the biosimilar story is not niche pharma plumbing anymore — it is one of the largest commercial openings in drug development. ### What is a biosimilar, exactly? A biosimilar is not a perfect copy in the way a generic pill is. These drugs are large, complex proteins, so the bar is “highly similar” with no meaningful clinical differences, not atom-for-atom identity. That makes development slower, more regulated, and more manufacturing-heavy — but still much cheaper and less risky than inventing a brand-new biologic from scratch. ### Why is Keytruda the center of gravity? Because it is enormous. Keytruda is Merck’s anti–PD-1 checkpoint inhibitor and one of the biggest drugs in the world, used across a long list of cancers. With 2025 sales at $31.7 billion, even modest biosimilar penetration would move billions of dollars in revenue and pricing power. That is why people keep treating the 2028 date like a starting gun. ### Why does 2028 matter so much? The IV version of pembrolizumab — Keytruda’s core franchise — is projected to lose U.S. patent protection in 2028. Some developers are already far enough along that filings could reach FDA in 2026 or 2027, which would let them line up approvals ahead of launch. In other words, the market is being prepared now, even if the real price war starts later. ### Is this just one drug? Not even close. IQVIA’s big point is that the U.S. is heading into a much broader biologics expiry cycle: 118 biologics are expected to lose patent protection from 2025 through 2034, representing $234 billion in loss-of-exclusivity opportunity. Average annual sales exposure is about $23 billion — much higher than the prior decade. Keytruda is the headline act, but the stage is much bigger. ### So why isn’t everyone piling in? Because biosimilars are still hard. You need cell-line engineering, process development, analytical comparability work, clinical packages, regulatory expertise, and commercial muscle with hospitals and payers. IQVIA’s catch is brutal: about 90% of those 118 biologics currently have no biosimilars in development. So the opportunity is huge, but the field is not infinitely crowded. ### Where do synthetic-biology startups fit? This is where the story gets interesting. A startup that can build biologics faster, cheaper, or more reproducibly does not have to bet everything on discovering a first-in-class drug. It can target a known molecule with known demand and a visible patent-expiry window. Basically, be an inference from the market setup — but it fits the shape of the opening. ### What is the real bottleneck? Manufacturing. In small-molecule generics, chemistry is the moat-crossing exercise. In biosimilars, manufacturing is the product. The hard part is not just making the protein once — it is making it consistently, at scale, with the same glycosylation, folding, purity, and stability profile ever. ### Bottom line? The important shift is not a single approval today. It is that the next biologics patent wave is now visible enough to underwrite real company-building. Keytruda makes the opportunity feel concrete, but the broader message is bigger: biosimilars are turning from a side market into one of the main ways biotech platforms can become actual businesses.